Literature DB >> 14693561

Effect of heat-treated amphotericin B on renal and fungal cytotoxicity.

Karen Bartlett1, Edwin Yau, Scott C Hartsel, Alison Hamer, Gina Tsai, Dan Bizzotto, Kishor M Wasan.   

Abstract

The purpose of this investigation was to determine the cytotoxicity of amphotericin B (AMB; trade name Fungizone [FZ]) following the administration of FZ and a heat-treated form of FZ (HFZ) to LLC-PK(1) pig kidney cells and Cryptococcus neoformans var. gattii cells. HFZ was significantly less toxic to kidney cells than FZ at all concentrations tested. For both FZ and HFZ, the concentration range which resulted in a 50% reduction of the growth of fungal cells was 0.125 to 1 mg/ml. These findings suggest that heat treatment decreases AMB's renal cytotoxicity without modifying its antifungal activity.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14693561      PMCID： PMC310175          DOI： 10.1128/AAC.48.1.333-336.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia.

Authors:  Craig Stephen; S Lester; W Black; M Fyfe; Stephen Raverty
Journal:  Can Vet J       Date:  2002-10       Impact factor: 1.008

2.  In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?

Authors:  C E Swenson; W R Perkins; P Roberts; I Ahmad; R Stevens; D A Stevens; A S Janoff
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 3.  Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs.

Authors:  K M Wasan; S M Cassidy
Journal:  J Pharm Sci       Date:  1998-04       Impact factor: 3.534

4.  Heat treatment of amphotericin b modifies its serum pharmacokinetics, tissue distribution, and renal toxicity following administration of a single intravenous dose to rabbits.

Authors:  E H Kwong; M Ramaswamy; E A Bauer; S C Hartsel; K M Wasan
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

5.  Heat-induced superaggregation of amphotericin B modifies its interaction with serum proteins and lipoproteins and stimulation of TNF-alpha.

Authors:  S C Hartsel; B Baas; E Bauer; L T Foree; K Kindt; H Preis; A Scott; E H Kwong; M Ramaswamy; K M Wasan
Journal:  J Pharm Sci       Date:  2001-02       Impact factor: 3.534

6.  Activity and kinetics of dissociation and transfer of amphotericin B from a novel delivery form.

Authors:  B Baas; K Kindt; A Scott; J Scott; P Mikulecky; S C Hartsel
Journal:  AAPS PharmSci       Date:  1999

7.  In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating.

Authors:  C Petit; M Chéron; V Joly; J M Rodrigues; J Bolard; F Gaboriau
Journal:  J Antimicrob Chemother       Date:  1998-12       Impact factor: 5.790

8.  A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology.

Authors:  D S Burgess; R W Hastings
Journal:  Diagn Microbiol Infect Dis       Date:  2000-10       Impact factor: 2.803

9.  Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies.

Authors:  K M Wasan; A L Kennedy; S M Cassidy; M Ramaswamy; L Holtorf; J W Chou; P H Pritchard
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani.

Authors:  C Petit; V Yardley; F Gaboriau; J Bolard; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191
View more
  5 in total

1.  Heat-treated Fungizone retains amphotericin B antifungal activity without renal toxicity in rats infected with Aspergillus fumigatus.

Authors:  Olena Sivak; Karen Bartlett; Kishor M Wasan
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

2.  Amphotericin B-induced renal tubular cell injury is mediated by Na+ Influx through ion-permeable pores and subsequent activation of mitogen-activated protein kinases and elevation of intracellular Ca2+ concentration.

Authors:  Takahisa Yano; Yoshinori Itoh; Eiko Kawamura; Asuka Maeda; Nobuaki Egashira; Motohiro Nishida; Hitoshi Kurose; Ryozo Oishi
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

Review 3.  Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy.

Authors:  Célia Faustino; Lídia Pinheiro
Journal:  Pharmaceutics       Date:  2020-01-01       Impact factor: 6.321

4.  Biomimetically engineered Amphotericin B nano-aggregates circumvent toxicity constraints and treat systemic fungal infection in experimental animals.

Authors:  Qamar Zia; Owais Mohammad; Mohd Ahmar Rauf; Wasi Khan; Swaleha Zubair
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

5.  Amphotericin B release rate is the link between drug status in the liposomal bilayer and toxicity.

Authors:  Yuri Svirkin; Jaeweon Lee; Richard Marx; Seongkyu Yoon; Nelson Landrau; Md Abul Kaisar; Bin Qin; Jin H Park; Khondoker Alam; Darby Kozak; Yan Wang; Xiaoming Xu; Jiwen Zheng; Benjamin Rivnay
Journal:  Asian J Pharm Sci       Date:  2022-06-08       Impact factor: 9.273
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.